John A. Bittl works in Interventional / Structural Cardiology affiliated with American College of Cardiology.
John A. Bittl, MD, FACC is an interventional cardiologist who serves as a Senior Consulting Editor for JACC (Interventions) and as a volunteer member of the American College of Cardiology Scientific Publications Committee. He practiced interventional cardiology at AdventHealth Ocala (formerly Munroe Regional Medical Center) from 1997 to 2021 and previously served on the faculty at Harvard Medical School as an associate professor of medicine at Brigham and Women's Hospital. He received his MD from Johns Hopkins University School of Medicine in 1979 and completed cardiology fellowship training at Brigham and Women's Hospital.
264 pubs · 28,276 cites · h-index 66
MD
Johns Hopkins University School of Medicine
1979
Senior Consulting Editor, JACC, and Volunteer Member, Scientific Publications Committee
American College of Cardiology · 2020 - Present
Interventional Cardiologist
AdventHealth Ocala · 1997 - 2021
Associate Professor of Medicine
Harvard Medical School · 1984 - 1997
Cardiologist
Brigham and Women's Hospital · 1982 - 1997
Physician, University of Washington
The data to date still do not indicate that PCI, really under any circumstance outside of acute coronary syndromes, prolongs life, and therefore I think [it's important to emphasize] a more conservative approach…. What's happening in practice got a bit ahead of the evidence.
CirculationFihn et al.
Systematic review assesses clinical outcomes related to dual antiplatelet therapy duration in patients with coronary artery disease, suggesting updated guidelines.
May support excimer laser use in thrombus lesions; hypothesis-generating and should not change practice pending larger trials.
This guideline provides anatomical and clinical criteria to guide the choice between PCI and CABG in patients with stable ischemic heart disease.
The 2021 ACC/AHA/SCAI guideline provides updated, patient-centric recommendations for the treatment of patients with significant coronary artery disease undergoing revascularization.
Should guide revascularization in significant CAD; extends prior guidelines by incorporating recent RCT data.
JACC Editor-in-Chief, Yale University · Yale University
Although the title is framed around acute PE, the text rightly underscores that the impact of PE extends beyond the initial event. Longitudinal management has become essential to optimize patient outcomes and reduce the long-term burden of this complex disease.
Journal of the American College of CardiologyBikdeli et al.
Professor of medicine, Baylor College of Medicine · Baylor College of Medicine
While we knew that treating the culprit artery that is completely blocked by implanting a stent is beneficial, it was previously not considered safe to treat other partially blocked (nonculprit) arteries during the same procedure.
Journal of the American College of CardiologyLevine et al.
This case series illustrates the practical application of the 2021 ACC/AHA/SCAI revascularization guidelines in managing patients with stable ischemic heart disease and complex coronary disease.
Transradial artery access for percutaneous coronary intervention is associated with lower bleeding and vascular complications than transfemoral artery access, especially in patients with acute coronary syndromes. A growing body of evidence supports adoption of transradial artery access to improve acute coronary syndrome-related outcomes, to improve healthcare quality, and to reduce cost. The purpose of this scientific statement is to propose and support a "radial-first" strategy in the United States for patients with acute coronary syndromes. This document also provides an update to previously published statements on transradial artery access technique and best practices, particularly as they relate to the management of patients with acute coronary syndromes.
Reinforces Class I CABG preference in diabetic multivessel disease; extends FREEDOM trial via Bayesian synthesis but leaves open prospective validation.
No mortality signal with 12-month DAPT may support shorter regimens; leaves open individualized duration trials.
